Wei‐Sen Lam

407 total citations
15 papers, 230 citations indexed

About

Wei‐Sen Lam is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Wei‐Sen Lam has authored 15 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Wei‐Sen Lam's work include Occupational and environmental lung diseases (5 papers), Cancer Research and Treatments (3 papers) and Fibroblast Growth Factor Research (3 papers). Wei‐Sen Lam is often cited by papers focused on Occupational and environmental lung diseases (5 papers), Cancer Research and Treatments (3 papers) and Fibroblast Growth Factor Research (3 papers). Wei‐Sen Lam collaborates with scholars based in Australia, United States and Taiwan. Wei‐Sen Lam's co-authors include Anna K. Nowak, Martin R. Stockler, W. Joost Lesterhuis, Connull Leslie, Nick Pavlakis, Sonia Yip, Peey‐Sei Kok, Chris Brown, Deme Karikios and Brett Hughes and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Wei‐Sen Lam

14 papers receiving 226 citations

Peers

Countries citing papers authored by Wei‐Sen Lam

Since Specialization

Citations

This map shows the geographic impact of Wei‐Sen Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei‐Sen Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei‐Sen Lam more than expected).

Fields of papers citing papers by Wei‐Sen Lam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wei‐Sen Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei‐Sen Lam. The network helps show where Wei‐Sen Lam may publish in the future.

Co-authorship network of co-authors of Wei‐Sen Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Wei‐Sen Lam. A scholar is included among the top collaborators of Wei‐Sen Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wei‐Sen Lam. Wei‐Sen Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia 2025 ·Pathology ·Wendy A. Cooper, (unknown), Caroline Cooper, Stephen B. Fox, (unknown), Peter J. Jessup, Sonja Klebe, Wei‐Sen Lam, Trishe Leong, Zarnie Lwin, Rachel Roberts‐Thomson, Benjamin Solomon, Rebecca Tay, Rebecca Trowman, Janet Wale, Nick Pavlakis	1
2	Recommendations for molecular testing of lung cancer in Australia: consensus guidelines from the Royal College of Pathologists of Australasia and the Thoracic Oncology Group of Australasia 2025 ·Pathology ·Wendy A. Cooper, (unknown), Caroline Cooper, Stephen B. Fox, (unknown), Peter J. Jessup, Sonja Klebe, Wei‐Sen Lam, Trishe Leong, Zarnie Lwin, Rachel Roberts‐Thomson, Benjamin Solomon, Rebecca Tay, Janney Wale, Nick Pavlakis	0
3	Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy 2023 ·Cancer Medicine ·(unknown), Robert U. Newton, Daniel A. Galvão, Dennis R. Taaffe, Pedro López, Tarek Meniawy, (unknown), Wei‐Sen Lam, Elin S. Gray, Favil Singh	8
4	Specialist pharmacist consultations with cancer patients in a pharmacist‐led anticancer clinic 2022 ·Asia-Pacific Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Wei‐Sen Lam, Paul Cannell, (unknown), Bruce Sunderland, Petra Czarniak	2
5	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1‐3 tyrosine kinase inhibitor anticancer therapy 2021 ·Clinical and Experimental Ophthalmology ·Jason Charng, Mary S. Attia, (unknown), Wei‐Sen Lam, Jenette Creaney, Sanjeevan Muruganandan, Catherine Read, Michael Millward, (unknown), Aron Chakera, Gary Lee, Anna K. Nowak, Fred K. Chen	5
6	Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET 2021 ·Endocrine Related Cancer ·Murali Kesavan, (unknown), Wei‐Sen Lam, Phillip G. Claringbold, J. Harvey Turner	19
7	Intravitreal dexamethasone implant use as first-line therapy for cancer-associated retinopathy 2021 ·BMJ Case Reports ·(unknown), (unknown), Wei‐Sen Lam, (unknown)	6
8	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in 2020 ·The Lancet Oncology ·Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok, Chris Brown, Brett Hughes, Deme Karikios, Thomas John, Steven Kao, Connull Leslie, Alistair Cook, Nick Pavlakis, Karen Briscoe, Kenneth J. O’Byrne, Christos S. Karapetis, Wei‐Sen Lam, Ailsa Langford, Sonia Yip, Martin R. Stockler	115
9	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma 2019 ·Lung Cancer ·Wei‐Sen Lam, Jenette Creaney, Fred K. Chen, Wee Loong Chin, Sanjeevan Muruganandan, (unknown), Mary S. Attia, Catherine Read, Kevin Murray, Michael Millward, (unknown), Aron Chakera, Gary Lee, Anna K. Nowak	27
10	KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non–small cell lung cancer (NSCLC) 2019 ·Annals of Oncology ·Martin Gutierrez, Wei‐Sen Lam, Matthew D. Hellmann, Matthew A. Gubens, Charu Aggarwal, Daniel S.W. Tan, Enriqueta Felip, Joanne Chiu, Jun S. Lee, J.C.-H. Yang, Edward B. Garon, Andrea Basso, Hua Ma, Lawrence Fong, Alexandra Snyder, Jianda Yuan, Roy S. Herbst	2
11	DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. 2018 ·Journal of Clinical Oncology ·Anna K. Nowak, W. Joost Lesterhuis, Brett Hughes, Chris Brown, Peey‐Sei Kok, Kenneth J. O’Byrne, Thomas John, Nick Pavlakis, Steven Kao, Sonia Yip, Deme Karikios, Wei‐Sen Lam, Ailsa Langford, Martin R. Stockler	15
12	P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress 2017 ·Journal of Thoracic Oncology ·Wei‐Sen Lam, Gary Lee, Jenette Creaney, Sanjeevan Muruganandan, Michael Millward, Catherine Read, Anna K. Nowak	2
13	P2.06-025 DREAM - A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In 2017 ·Journal of Thoracic Oncology ·Anna K. Nowak, Peey‐Sei Kok, Ann Livingstone, W. Joost Lesterhuis, Sonia Yip, Mark W. Donoghoe, Wei‐Sen Lam, Martin R. Stockler	1
14	Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma 2016 ·Pigment Cell & Melanoma Research ·Nima Mesbah Ardakani, Connull Leslie, (unknown), Wei‐Sen Lam, Charley Budgeon, Michael Millward, Benhur Amanuel	12
15	Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC) 2005 ·Journal of Clinical Oncology ·M. Christine Cripps, Mark Vincent, Derek J. Jonker, Ian G. Kerr, B. Dingle, Laurence Martin, (unknown), James Biagi, (unknown), Wei‐Sen Lam	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact